资讯

PR Newswire20 天
Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for ...
DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases Unique mechanism of action with ...
PharmiWeb21 天
Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for ...
DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases Unique mechanism of action with ...